Prostate Cancer Clinical Trial

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Summary

This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.

View Full Description

Full Description

The study will include a group of 26 patients with metastatic prostate cancer. Each patient will be administered a 7-9 mCi intravenous dose of copper Cu 64 PSMA I&T injection. PET/CT images will be acquired for all patients at 1 hour ± 15 minutes and 4 hours ± 30 minutes post copper Cu 64 PSMA I&T injection.

The PET/CT images will be interpreted independently by three readers blinded to all patient information. Each patient study will be assessed and scored for the detection of prostate cancer. Specifically, each reader will categorize images as "Disease" or "No Disease" based only on tumor uptake of copper Cu 64 PSMA-I&T in each of the four regions: 1) prostate bed or prostate gland, 2) lymph nodes (pelvic and extra pelvic), 3) bone, and 4) viscera/soft tissue. Analysis of the reads will be used for determination of the CLR and CDR for 1 hour and 4-hour post-injection imaging of copper Cu 64 PSMA I&T PET/CT by comparison to the Composite Reference Standard.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with histologically proven prostate adenocarcinoma.
Prior radical prostatectomy or radiation therapy with curative intent.

Recurrence of disease defined as:

Prior Radical Prostatectomy: PSA > 0.2 ng/mL, or
Prior Radiation Therapy: 2 ng/mL rise in PSA over post-treatment nadir
Patients with at least one extraprostatic site of disease suspected based on prior imaging or diagnosed by biopsy.
Age greater than or equal to 18 years.
Able to understand and provide signed written informed consent.

Exclusion Criteria:

Androgen deprivation therapy (ADT) or other therapies targeting the androgen pathway, unless subject has a rising PSA level.
Body weight greater than 350 lb (158 kg).
Investigational therapy within the past 30 days.
Creatinine clearance (ClCr) less than 30 mL/min.
Participants who are capable of fathering a child and who are unwilling to take precautions to prevent pregnancy.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

29

Study ID:

NCT05653856

Recruitment Status:

Completed

Sponsor:

Curium US LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

Yale University
New Haven Connecticut, 06520, United States
Edward Hines, Jr. VA Hospital
Hines Illinois, 60141, United States
Johns Hopkins University
Baltimore Maryland, 21287, United States
Saint Louis University
Saint Louis Missouri, 63104, United States
John J. Cochran Veterans Hospital
Saint Louis Missouri, 63106, United States
Washington University
Saint Louis Missouri, 63110, United States
Nebraska Cancer Specialists
Omaha Nebraska, 68130, United States
XCancer Omaha/Urology Cancer Center
Omaha Nebraska, 68130, United States
MD Anderson
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

29

Study ID:

NCT05653856

Recruitment Status:

Completed

Sponsor:


Curium US LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.